{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:42Z","timestamp":1785308322768,"version":"3.55.0"},"reference-count":20,"publisher":"Baskent University","issue":"Supp 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.6002\/ect.mesot2025.l35","type":"journal-issue","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:52:38Z","timestamp":1785228758000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Nobakht E, Jagadeesan M, Paul R, Bromberg J, Dadgar S. Precision medicine in kidney transplantation: just hype or a realistic hope? Transplant Direct. 2021;7(2):e650. doi:10.1097\/TXD.0000000000001102","DOI":"10.1097\/TXD.0000000000001102"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013;26(7):662-672. doi:10.1111\/tri.12043","DOI":"10.1111\/tri.12043"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Special Issue: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1-S155. doi:10.1111\/j.1600-6143.2009.02834.x","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Sanchez-Fructuoso AI, Perez-Flores I, Valero R, et al. The Polymorphism -308G\/A of tumor necrosis factor-alpha gene modulates the effect of immunosuppressive treatment in first kidney transplant subjects who suffer an acute rejection. J Immunol Res. 2016;2016:2197595. doi:10.1155\/2016\/2197595","DOI":"10.1155\/2016\/2197595"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Cvetkovski F, Razavi R, Sellberg F, Berglund E, Berglund D. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro. Am J Transplant. 2023;23(10):1603-1611. doi:10.1016\/j.ajt.2023.05.032","DOI":"10.1016\/j.ajt.2023.05.032"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Hart A, Lentine KL, Smith JM, et al. OPTN\/SRTR 2019 annual data report: kidney. Am J Transplant. 2021;21 Suppl 2:21-137. doi:10.1111\/ajt.16502","DOI":"10.1111\/ajt.16502"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005;16(7):2234-2240. doi:10.1681\/ASN.2004100844","DOI":"10.1681\/ASN.2004100844"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388(10063):3006-3016. doi:10.1016\/S0140-6736(16)32187-0","DOI":"10.1016\/S0140-6736(16)32187-0"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Ekberg J, Enevoldsen AA, Wallquist C, et al. Steroid avoidance with low-dose tacrolimus is safe and effective in the long-term for kidney transplant recipients. Kidney Int Rep. 2025;10(9):3102-3112. doi:10.1016\/j.ekir.2025.06.016","DOI":"10.1016\/j.ekir.2025.06.016"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Fontova P, Colom H, Rigo-Bonnin R, et al. Influence of the circadian timing system on tacrolimus pharmacokinetics and pharmacodynamics after kidney transplantation. Front Pharmacol. 2021;12:636048. doi:10.3389\/fphar.2021.636048","DOI":"10.3389\/fphar.2021.636048"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Stifft F, Undre N, van Hooff JP, Christiaans MH. Effect of breakfast on the exposure of the once-daily tacrolimus formulation in stable kidney transplant recipients. Ther Drug Monit. 2016;38(4):456-462. doi:10.1097\/FTD.0000000000000311","DOI":"10.1097\/FTD.0000000000000311"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Stifft F, Vanmolkot F, Scheffers I, van Bortel L, Neef C, Christiaans M. Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2014;78(5):996-1004. doi:10.1111\/bcp.12420","DOI":"10.1111\/bcp.12420"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Peeters LEJ, Andrews LM, Hesselink DA, de Winter BCM, van Gelder T. Personalized immunosuppression in elderly renal transplant recipients. Pharmacol Res. 2018;130:303-307. doi:10.1016\/j.phrs.2018.02.031","DOI":"10.1016\/j.phrs.2018.02.031"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77-89. doi:10.1038\/clpt.2011.104","DOI":"10.1038\/clpt.2011.104"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Salvadori M, Tsalouchos A. Biomarkers in renal transplantation: an updated review. World J Transplant. 2017;7(3):161-178. doi:10.5500\/wjt.v7.i3.161","DOI":"10.5500\/wjt.v7.i3.161"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Ma BM, Elefant N, Tedesco M, et al. Developing a genetic testing panel for evaluation of morbidities in kidney transplant recipients. Kidney Int. 2024;106(1):115-125. doi:10.1016\/j.kint.2024.02.021","DOI":"10.1016\/j.kint.2024.02.021"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Zheng S, Tasnif Y, Hebert MF, et al. CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. Transplantation. 2013;95(6):821-827. doi:10.1097\/TP.0b013e31827e6ad9","DOI":"10.1097\/TP.0b013e31827e6ad9"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Abdel-Kahaar E, Winter S, Tremmel R, et al. The Impact of CYP3A4*22 on tacrolimus pharmacokinetics and outcome in clinical practice at a single kidney transplant center. Front Genet. 2019;10:871. doi:10.3389\/fgene.2019.00871","DOI":"10.3389\/fgene.2019.00871"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Krall P, Yanez D, Rojo A, et al. CYP3A5 and UGT1A9 polymorphisms influence immunosuppressive therapy in pediatric kidney transplant recipients. Front Pharmacol. 2021;12:653525. doi:10.3389\/fphar.2021.653525","DOI":"10.3389\/fphar.2021.653525"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Rebollo-Mesa I, Nova-Lamperti E, Mobillo P, et al. Biomarkers of tolerance in kidney transplantation: are we predicting tolerance or response to immunosuppressive treatment? Am J Transplant. 2016;16(12):3443-3457. doi:10.1111\/ajt.13932","DOI":"10.1111\/ajt.13932"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:59:56Z","timestamp":1785304796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/supplement\/2026\/24\/6\/2\/20\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"journal-issue":{"issue":"Supp 2","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2025.l35","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}